keyboard_arrow_up

Skin And Soft Tissue Infections Pipeline Review and Market Analysis, H1 2015

This report provides comprehensive information on the therapeutic development for Skin And Soft Tissue Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Some of the Company profiles mentioned in this report are Atox Bio Inc., Debiopharm International S.A., Melinta Therapeutics, MicuRx Pharmaceuticals, Phosphagenics Limited. It also reviews key players involved in the therapeutic development for Skin And Soft Tissue Infections and special features on late-stage and discontinued projects.Get a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=403521 . (This is a premium report price at US$2000 for a single user PDF license)

Scope

- The report provides a snapshot of the global therapeutic landscape of Skin And Soft Tissue Infections

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in the therapeutics development for Skin And Soft Tissue Infections and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Skin And Soft Tissue Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.